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Background/aim: Stigma can be defined as a negative perception of chronically ill patients by their relatives or by society, or a similar
self-perception by the patients themselves. We aimed to validate the Turkish version of the Neuroquality of Life (Neuro-QoL)-Stigma
Scale for neurologic diseases.
Materials and methods: Forms were filled out by a total of 152 randomized patients under regular follow-up in the outpatient clinic (29
polyneuropathy, 25 epilepsy, 23 stroke, 24 tension-type headache, 28 multiple sclerosis, 27 Parkinson disease). The forms consisted of
the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), WHOQOL-BREF quality of life scale, the Multidimensional Scale
of Perceived Social Support (MSPSS), the General Self-Efficacy (GSE) scale, and the Neuro-QoL-Stigma scale.
Results: The internal consistency of the Neuro-QoL-Stigma scale showed Cronbach’s α coefficients of 0.95 for all groups. The mean
scores of the stigma scales were 33.42 ± 13.91 (min–max: 24–87). There were strong negative correlations between high stigma scores
and GSE-T, MSPSS-T, and WHOQOL-BREF, and a positive correlation with the BDI and BAI.
Conclusion: The Turkish version of Neuro-QoL-Stigma has satisfactory content validity and high internal consistency. Neuro-QoLStigma is suitable for understanding stigmatization in different neurological disorders in the Turkish population. The scale is available
for use at http://www.healthmeasures.net/explore-measurement-systems/neuro-qol.
Key words: Stigma, neurology, Neuro-QoL, validation

1. Introduction
Stigmatization is the negative labeling of an individual or
specific situation and this labeling results in the exclusion
of the individual from society (1). Stigmatization worsens
the quality of life (QoL), increases public prejudice, causes
a reduction in the perception of self-worth, has negative
physical and psychological consequences, and disrupts
work and family life (2–4). Stigma is a term used frequently
in relation to mental disorders, but it is still uncommon
to evaluate stigmatization in the context of neurological
diseases (5). However, the local burden and cultural
particulars of stigmatization should be further evaluated
using cross-cultural comparisons.
The various forms of stigma manifest themselves as
public stigma, self-stigma (internal), and label avoidance
in the DSM-V. Stigma scales target these three areas (6).
Assessment of stigmatization is very important because
stigmatization itself may result in delay in treatment

choice and decrease in treatment quality. Stigmatization in
neurological disorders has a severe effect on the patient’s
family and social relationships (7,8).
In Turkey, there is a limited number of studies that
evaluate stigmatization in neurological disorders such as
epilepsy, tension-type headache, and Parkinson disease,
and there is no scale used specifically for targeting
neurological disorders (9–12). Neuro-QoL is a scale
developed by the National Institute of Neurological
Disorders and Stroke. Neuro-QoL consists of 13 adult and
10 pediatric subgroup tests including physical, mental,
and social health (13). It is a health assessment tool that
is clinically and psychometrically appropriate for major
neurological disorders (i.e. stroke, epilepsy, multiple
sclerosis, amyotrophic lateral sclerosis, and Parkinson
disease) (14,15).
The stigma scale is one of the subscales of NeuroQoL for pediatrics and adults in both the hard copy and
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computerized version. The adult long version consists of
24 items and the short version consists of the first 8 items
of the long version (13).
Our aim was to evaluate the reliability and validity
of the adult long version of the Neuro-QoL-Stigma scale
in order to use it in clinical practice and research among
Turkish patients.
2. Materials and methods
2.1. Study design
The present study was established in two stages. The first
stage was the cross-cultural adaptation. A sequential
approach was followed in order to obtain linguistically
equivalent versions of the adult long version of the
Neuro-QoL stigma scale consisting of 24 items. Semantic
equivalence was achieved with two independent
translations into Turkish performed by two bilingual
Turkish experts and a consensus version, followed by a
final back-translation performed by another translator
whose native language was English and who was also
fluent in Turkish.
The quality analysis of the translations and the first
content validity were checked by a clinician’s review and
by a cognitive debriefing panel with 10 healthy literate
people. After completing the questionnaires, we asked
them to explain the complicated and difficult issues to
the participants. Corrections were made according to
suggestions deemed suitable.
In the second phase, the reliability and validity tests
of the Turkish version were examined. We evaluated the
internal consistency reliability and construct validity of
the stigma subscales of Neuro-QoL. Internal consistency
reliability was evaluated by examining the item-total
correlations and Cronbach’s alpha coefficients. The
item-total correlations were calculated by removing
each of the 24 items. We calculated and reported the
alphas when any one of the items was removed from the
instrument. Cronbach’s alpha was also reported for the
whole instrument. For Cronbach’s alpha, we considered
the following cut-off values: >0.7 (acceptable), >0.8
(good), and >0.9 (excellent). For item-total correlation,
we considered a value greater than 0.3 to be an indicator
that an item was related to the overall scale. Concurrent
validity was tested by comparing other related scales.
Stigma scores were calculated as a t-scores (50 is the mean
and 10 is the standard deviation) (16).
2.2. Patients
Patients with neurological diseases were consecutively
recruited from the outpatient clinic of our neurology
department. Six major neurological diseases were
identified: relapsing-remitting multiple sclerosis (MS),
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Parkinson disease (PD), ischemic stroke, tensiontype headache, generalized epilepsy, and chronic
polyneuropathy. Literate patients were preidentified in
terms of compliance to the test and those who scored 27
or higher on the Turkish version of the Mini Mental State
Examination (MMSE-T) (17) were enrolled in the study.
Sociodemographics and clinical characteristics including
age, sex, education, employment status, marital status, and
hospitalization were assessed.
2.3. Instruments
The Neuro-QoL stigma subscale consists of 24 items. Item
scores range from 1 (never) to 5 (always). A summary
index is calculated by adding all scores, ranging from 24 to
120, with higher scores reflecting the worst stigmatization
(13).
The World Health Organization’s Quality of
Life (WHOQOL)-BREF with 26 items is a generic measure
of health status comprising four major health dimensions
(physical health, psychological health, social relationships,
environment), all of them on a scale of 26–135, with
higher scores indicating full health status (18,19). In this
study, the Turkish version of the WHOQOL-BREF was
used (20).
The Beck Depression Inventory (BDI) with 21 items
is one of the popular depression measures. Scores are in
the range of 0–63, with higher scores indicating severe
depression. In this study, the Turkish version of the BDI
was used (21–23).
The Beck Anxiety Inventory (BAI) with 21 items is a
severity indicator for anxiety. Scores are in the range of
0–63, with higher scores indicating severe anxiety (24). In
this study, the Turkish version of the BAI was used (25).
The General Self-Efficacy (GSE) scale measures the
belief in one’s ability to complete activities related to one’s
own competency. The GSE contains 17 items, 6 of which
assess the level of positive self-esteem and 11 of which
evaluate the level of negative self-esteem. Each item is
scored from 1 (completely disagree) to 5 (completely
agree) (26). In this study, the Turkish version of the GSE
was used (27).
The Multidimensional Scale of Perceived Social Support
(MSPSS) is a research tool that assesses social support. It
consists of three subscales, each of them representing a
different source of support: family, friends, and significant
other. It contains 12 items rated on a seven-point Likerttype scale with scores ranging from ‘very strongly disagree’
(= 1) to ‘very strongly agree’ (= 7) (28). In this study, the
Turkish version of the MSPSS was used (29).
2.4. Statistical analysis
Descriptive statistics were applied to demographic and
questionnaire data. Internal consistency reliability was
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tested by Cronbach’s alpha indicator. Scores between 0.70
and 0.95 are considered as acceptable reliability indicators.
Concurrent validity was tested by comparing the measured
scores (one-way ANOVA with Tukey post hoc test for
pairwise comparisons) among known group variables
as well as by Pearson’s correlation coefficient. Pearson’s
correlation coefficients were computed following the same
criteria as above. P < 0.05 indicated statistical significance.
2.5. Ethics
Information about the research was given to all participants.
The study protocol and ethics procedures were approved
by the ethics board of our institution. Patients or their legal
guardians provided informed signed consent.
3. Results
From a total of 152 patients, 65% were female and 35%
were male. The mean age was 47.9 ± 17.6 years. The study
group consisted of 29 patients with polyneuropathy, 25
patients with epilepsy, 23 patients with stroke, 24 patients
with tension-type headache, 28 patients with MS, and 27
patients with PD.
Table 1 shows the mean scores, the standard deviations,
internal consistency correlations (ICCs), and Cronbach’s
α results for each domain of the Neuro-QoL-Stigma
scale. Table 2 shows the correlation matrix obtained and
the significance values. Comparing Neuro-QoL-Stigma
and other general measures, we found strong negative
correlations with the GSE, MSPSS, and WHOQOLBREF-T. We also found strong positive correlations with
the BDI and BAI. We found no significant correlation with
the family subdimension of the MSPSS.
T-scores of the Neuro-QoL-Stigma scale for each group
were 48.7 ± 11 for polyneuropathy, 49.1 ± 4.9 for epilepsy,
50.4 ± 11 for stroke, 45.2 ± 2.8 for headache, 51 ± 10.3 for
MS, and 55.2 ± 12.5 for PD. When comparing our patients’
Neuro-QoL stigma T-scores with mean clinical T-scores
of the Neuro-QoL study reference group (national), score
difference of less than 0.5 SD units were determined within
normal limits. When the groups were compared according
to T-score, there was a significant difference between the
headache and the PD group (P = 0.03).
4. Discussion
Stigma can be defined as a negative perception of
chronically ill patients by their relatives or by society, or a
similar self-perception by the patients themselves. Patients
try to hide their illness from other people because of their
feelings of embarrassment (30).
Stigma is usually associated with neurological
diseases as well as psychiatric illnesses so it is important
to use a scale that can evaluate stigma for neurologists.
With neurological diseases, stigma can lead to anxiety,

depression, and decreased self-esteem and diminished
life satisfaction. With the addition of long-term health
problems, quality of life can be negatively affected (31).
Our results showed a strong correlation with the scales
(GSE, BDI, BAI, MSPSS, and WHOQOL-BREF-T) in
support of the above information.
Rao et al. developed a stigma scale for chronic disease.
They described three types of stigmatization as follows:
perceived stigma (discriminatory attitude by society),
enacted stigma (experience of social prejudices), and selfstigmatization (internalization of negative behaviors and
low self-esteem) (7). Neuro-QoL Stigma also contains
such areas.
Various factors have been indicated in stigma studies in
neurological diseases. In a stigma study performed among
epilepsy patients, educational status, level of income, age at
onset of the disease, and frequency of seizures were shown
as influencing factors. Having adequate social support and
increased self-efficacy has been found to have a positive
effect on stigma scores. Increased knowledge of patients
about epilepsy and the presence of positive attitudes
towards epilepsy were associated with decreased stigma
scores in patients with epilepsy (32,33). Victorson et al.
reported that the T-score was 49.7 ± 9.1 in adult epilepsy
patients by using the Neuro-QoL stigma scale (34). In the
Neuro-QoL user manual, the T-score was defined as 50.6
± 6.7 for epilepsy (16). We found the T-score for epilepsy
to be 49.1 ± 4.9. This result is consistent with previous
studies.
PD patients have feelings of shame related to their
movement and communication difficulties. Patients who
cannot cope with social life due to their symptoms and
who withdraw from society will have to live alone in their
private world. Studies showed that higher stigma scores
were related to more severe PD symptoms (35). Nowinski
et al. showed that the stigma T-score was 48.39 ± 6.62 in
PD cases (36). The Neuro-QoL user manual described
the T-score as 49.29 ± 4.65 in PD (16). We found that the
T-score for PD was 55.2 ± 12.5. Our results are higher than
those of previous studies. This may be due to the possibly
high level of disability in our PD cases. Further studies are
required.
MS is one of the most common causes of severe disability
in young people. Apart from the neurological findings of
MS, stigmatization, which affects the quality of life, must
be considered by physicians. In stigma studies of MS, it
was found that higher Expanded Disability Status Scale
(EDSS) scores with higher age, longer disease duration,
and progressive forms are found to be responsible for
stigma (37,38). Miller et al. found average T-scores for MS
cases as 49.3 ± 7.23 by using the Neuro-QoL short form
(39). The Neuro-QoL user manual indicated the T-score as
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Table 1. Mean values and confidence intervals of reliability analysis for Neuro-QoL-Stigma scale. Variables presented as mean ±
standard deviation (SD) because of normal distribution. Cut-off values of Cronbach’s alpha are as follows: >0.78 (acceptable), >0.8
(good), and >0.9 (excellent). Internal consistency correlations (ICCs) are statistically significant at P ≤ 0.001.
Item no. Item

Mean ± SD

Cronbach’s α

ICC

1

Because of my illness, some people avoided me

1.32 ± 0.84

0.945

0.70

2

Because of my illness, I felt left out of things

1.30 ± 0.84

0.944

0.82

3

Because of my illness, people avoided looking at me

1.26 ± 0.74

0.945

0.74

4

I felt embarrassed about my illness

1.39 ± 0.90

0.945

0.73

5

Because of my illness, some people seemed uncomfortable with me

1.50 ± 0.90

0.945

0.70

6

I felt embarrassed because of my physical limitations

1.32 ± 0.79

0.944

0.77

7

Because of my illness, people were unkind to me

1.11 ± 0.37

0.947

0.67

8

Some people acted as though it was my fault I have this illness

1.30 ± 0.67

0.948

0.39

9

Because of my illness, I felt embarrassed in social situations

1.38 ± 0.94

0.944

0.78

10

Because of my illness, I felt emotionally distant from other people

1.60 ± 1.05

0.943

0.81

11

Because of my illness, people tended to ignore my good points

1.30 ± 0.71

0.947

0.59

12

Because of my illness, I was treated unfairly by others

1.24 ± 0.68

0.947

0.54

13

Because of my illness, I felt different from others

1.63 ± 1.04

0.943

0.82

14

Because of my illness, I worried about other people’s attitudes towards me

1.49 ± 1.01

0.944

0.79

15

Because of my illness, I worried that I was a burden to other

1.92 ± 1.19

0.945

0.71

16

Because of my illness, people made fun of me

1.08 ± 0.29

0.949

0.34

17

I was unhappy about how my illness affected my appearance

1.81 ± 1.25

0.948

0.60

18

Because of my illness, strangers tended to stare at me

1.32 ± 0.77

0.946

0.65

19

I lost friends by telling them that I have this illness

1.13 ± 0.49

0.948

0.42

20

Because of my illness, it was hard for me to stay neat and clean

1.46 ± 0.96

0.946

0.62

21

I felt embarrassed about my speech

1.30 ± 0.80

0.946

0.62

22

I avoided making new friends to avoid telling others about my illness

1.33 ± 0.87

0.945

0.69

23

I tended to blame myself for my problems

1.48 ± 0.92

0.946

0.66

24

People with my illness lost their jobs when their employers found out about it

1.42 ± 0.89

0.950

0.33

50.13 ± 5.2 for MS (16). We found this score as 51 ± 10.3
for MS.
Stroke-related stigma studies show that stroke survivors
who experience mild-to-moderate levels of stigma are
more likely to be depressed or have lower quality of life
(40). The mean stigma T-score was 51.94 ± 6.33 for stroke
patients in the Neuro-QoL user manual (16). We found the
T-score as 50.4 ± 11 for stroke patients.
It was found that tension-type headache is considerably
more stigmatized than migraine in headache studies;
patients may hide their symptoms and will not seek help or
treatment (41). Young et al. investigated stigma in patients
with episodic migraine, chronic migraine, and epilepsy.
They observed that patients with chronic migraine and
epilepsy had similar stigmatization. In their study, stigma
correlated with inability to work (42). In the current study,
we found the lowest T-score as 45.2 ± 2.8 in the headache
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group. Further studies are needed in different types of
headache.
In some polyneuropathy studies, it is found that
some new developments have decreased the burden of
stigmatism on patients and families over the past few
decades. This may be due to recent medical treatments,
primary care health professionals, and ongoing clinical
trials (43). We found that the T-score was 48.7 ± 11 for the
polyneuropathy group.
Stigma may vary according to cultural differences,
education level, and many other social and clinical factors.
If patients cannot accept or understand their diagnosis,
they cannot develop insight regarding their illness. This is
the most important cause of self-stigmatization of patients
(12).
Stigma should be studied since it often accompanies
neurological diseases. We aimed to evaluate the reliability
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Table 2. Correlation between Neuro-QoL-Stigma and the other generic measures.
The names of other generic measures

Neuro-QoL-Stigma (P)

GSE

–0.30**

MSPSS

–0.38**

MSPSS Family

–0.10

MSPSS Friends

–0.42**

MSPSS Significant Other

–0.34**

BDI

0.56**

BAI

0.46**

WHOQOL-BREF-T, physical health

–0.38**

WHOQOL-BREF, psychological health

–0.55**

WHOQOL-BREF, social relationships

–0.46**

WHOQOL-BREF, environment

–0.31**

GSE: General Self-Efficacy, MSPSS: Multidimensional Scale of Perceived
Social Support, BDI: Beck Depression Inventory, BAI: Beck Anxiety Inventory,
WHOQOL-BREF: World Health Organization Quality of Life-BREF, *P < 0.05,
**P < 0.01.

and validity of the stigma scale of the Neuro-QoL tool.
This scale can be used in clinical practice among different
neurological diseases to understand stigmatization and
it can be effective in treatment planning and prognosis

of neurological diseases. All parameters of the adult long
form of the Neuro-QoL-Stigma scale demonstrated high
internal consistency and it is suitable for the Turkish
population.
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